reports
- Sean Conroy
Allarity Therapeutics - Termination of coverage
Edison Investment Research is terminating coverage on PIERER Mobility (PMAG), Allarity Therapeutics (ALLR), WANdisco (WAND), Quantum Genomics (ALQGC), and Mondo TV (MTVI). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.
Allarity Therapeutics Announces Delisting and Last Day of Trading in t...
Allarity Therapeutics Announces Delisting and Last Day of Trading in the Company’s Shares on Nasdaq First North Press release Hørsholm, Denmark (December 13, 2021) — Allarity Therapeutics A/S (“Allarity A/S” or the “Company”) today announced that Nasdaq First North Growth Market Sweden (“Nasdaq First North”) has accepted the Company’s application to delist the shares of Allarity A/S. Allarity A/S submitted the application immediately after publishing the Company’s press release of December 11, 2021, announcing the intention to delist. Nasdaq First North has published its decision (668...
Allarity Therapeutics Announces Shareholder Acceptance of Share Swap O...
Allarity Therapeutics Announces Shareholder Acceptance of Share Swap Offer and Initiates Delisting of the Company’s Shares from Nasdaq First North Press release Hørsholm, Denmark (December 11, 2021) — Allarity Therapeutics A/S (“Allarity A/S” or the “Company”) today announced that in excess of 94 % of the Company’s shareholders have accepted the Share Swap Offer, announced on November 24 and expired on December 9, pending final reconciliation. Considering the very high acceptance rate, the Board of Directors has as of today resolved to complete the Share Swap Offer. More...
Allarity Therapeutics A/S Publishes Offer Document Offering to Acquire...
Allarity Therapeutics A/S Publishes Offer Document Offering to Acquire Company Shares in Exchange for Shares in Allarity Therapeutics, Inc. with the Intent to Complete Recapitalization Press release Hørsholm, Denmark (November 24, 2021) — Allarity Therapeutics A/S ("Allarity A/S" or the "Company") hereby announces a voluntary offer and offer document to the shareholders of Allarity A/S to acquire all shares in Allarity A/S (the "Offer"), with the intent of completing the Company's recapitalization and reorganization ("Recapitalization") into a US holding company (Allarity Therapeutics, I...
Grant of New Warrants and Resolutions on Existing Warrants
Grant of New Warrants and Resolutions on Existing Warrants Company Announcement Hørsholm, Denmark (November 24, 2021) — Allarity Therapeutics A/S ("Allarity" or the "Company") today announced that the Board of Directors of Allarity has exercised the authorization granted by the shareholders at the Extraordinary General Meeting held on November 22, 2021, to issue new warrants. The Board has resolved to grant a total of 51,292,653 warrants as a part of a new incentive program for the Board of Directors, employees and consultants in Allarity. All warrants are issued free of charge and are i...
Allarity Therapeutics Publishes Interim Report for the Period January ...
Allarity Therapeutics Publishes Interim Report for the Period January – September 2021 Press Release Hørsholm, Denmark (November 23, 2021) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announces the publication of its Interim Report for the period January – September 2021. The report is available as an attached document and on the company’s website. Steve Carchedi, CEO of Allarity Therapeutics, commented on the company’s accomplishments during the period, stating, “It continues to be an exciting time for Allarity and the third quarter of 2021 was no exception. We are now...
Minutes of Extraordinary General Meeting held on 22 November 2021
Minutes of Extraordinary General Meeting held on 22 November 2021 Company Announcement Minutes of Extraordinary General Meeting held on 22 November 2021The English part of this parallel document in Danish (attached) and English is an unofficial translation of the original Danish text. In the event of disputes or misunderstandings arising from the interpretation of the translation, the Danish language shall prevail. Extract from extraordinary general meeting On 22 November 2021 extraordinary general meeting was held in Allarity Therapeutics A/S(the “Company”)CBR: 28106351 at Mazanti-A...
Allarity Therapeutics’ Oral PARP Inhibitor, Stenoparib, Demonstrates P...
Allarity Therapeutics’ Oral PARP Inhibitor, Stenoparib, Demonstrates Pre-clinical Antiviral Activity Against Delta Variant of Coronavirus Current positive results with delta variant B.1.617.2 follows previous pre-clinical tests, including testing of alpha variant B.1.1.7 (“British” variant),beta variant B.1351 (“South African” variant), and gamma variant P.1 (“Brazilian” variant). Allarity Therapeutics is planning to submit findings to U.S. National Institutes of Health (NIH) for funding opportunities as part of the new Antiviral Program for Pandemics (APP) Press ReleaseHørsholm...
NOTICE OF THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS OF ALLARIT...
NOTICE OF THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS OF ALLARITY THERAPEUTICS A/S TO BE HELD ON NOVEMBER 22, 2021 Press release THE BOARD OF DIRECTORS HEREBY CONVENES an extraordinary general meeting of the shareholders of Allarity Therapeutics A/S (“Allarity A/S”) to be held on November 22, 2021 at 10:00 am Central European Time at the offices of Mazanti-Andersen Advokatpartnerselskab, Amaliegade 10, DK-1256 Copenhagen K, Denmark (the “Allarity A/S Extraordinary General Meeting”). You will be able to follow the Allarity A/S Extraordinary General Meeting via live webcast in English...
U.S. SEC Issues Order Declaring Allarity Therapeutics Inc.’s Form S-4 ...
U.S. SEC Issues Order Declaring Allarity Therapeutics Inc.’s Form S-4 Registration Statement Effective Ahead of Planned Transition to U.S. Nasdaq An application for listing on the U.S. Nasdaq Stock Market for the shares of Allarity Therapeutics, Inc. (Delaware) (Nasdaq: ALLR) has been made conditioned upon shareholder approval of the Company’s Recapitalization Share ExchangeThe Recapitalization Share Exchange of the Company is subject to approval by the Company’s shareholders Press releaseHørsholm, Denmark (November 5, 2021) — Allarity Therapeutics A/S (“Allarity” or the “Company”) to...
Allarity Therapeutics and Lonza Collaborate to Manufacture Dovitinib, ...
Allarity Therapeutics and Lonza Collaborate to Manufacture Dovitinib, a Renal Cell Carcinoma Candidate Integrated solution for process development and manufacturing of drug substance and drug product will facilitate the advancement of clinical developmentThe agreement meets Allarity’s needs for current and future commercial production of dovitinib and will support the Company’s planned NDA filing in 2021 Basel, Switzerland and Hoersholm, Denmark, 23 September 2021 – Allarity Therapeutics A/S, a clinical-stage precision medicine company actively advancing a pipeline of in-licensed onco...
Allarity Therapeutics Presents Dovitinib Survival Data from DRP® Scree...
Allarity Therapeutics Presents Dovitinib Survival Data from DRP® Screened RCC Patients at ESMO 2021 Virtual Congress Patient selection using DRP® score of 50% resulted in a median survival of 15.0 monthPatient selection using DRP® score of 67% resulted in a median survival of 20.6 months Press Release Hørsholm, Denmark (September 16, 2021) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced validation results for its Dovitinib DRP® companion diagnostic utilizing data from Novartis’ prior Phase III trial of dovitinib in renal cell carcinoma (RCC), which will be incl...
Update: Allarity Therapeutics Receives Approximately SEK 23.3 Million ...
Update: Allarity Therapeutics Receives Approximately SEK 23.3 Million (US $2.7 Million) from Subscription to Warrants of Series ALLR TO 2 and TO 3 Subscription is approximately 9.5 percent of total outstanding TO 3 warrants Allarity’s Chairman of the Board and largest shareholder (Sass & Larsen ApS) participated in the subscription Press ReleaseHørsholm, Denmark (September 15, 2021) CORRECTION: The press release that the company published on September 14, 2021, at 23:06 CEST, contained an incomplete computation of the number of subscribed shares. The correct number of subscribed shares s...
Allarity Therapeutics Receives Approximately SEK 16.5 Million (US $1.9...
Allarity Therapeutics Receives Approximately SEK 16.5 Million (US $1.9 Million) from Subscription to Warrants of Series ALLR TO 3 Subscription is approximately 6.7 percent of total outstanding TO 3 warrants Allarity’s Chairman of the Board and largest shareholder (Sass & Larsen ApS) participated in the subscription Press Release Hørsholm, Denmark (September 14, 2021) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announces the outcome of the exercise of the warrants of series ALLR TO 3 that were issued in connection with the Company’s issue of units in June 20...
MINUTES OF EXTRAORDINARY GENERAL MEETING 2021
MINUTES OF EXTRAORDINARY GENERAL MEETING 2021 31 August 2021 ALLARITY THERAPEUTICS A/S On 31 August 2021 at 13:00 (CEST), an extraordinary general meeting of shareholders (the "General Meeting") of Allarity Therapeutics A/S, company registration (CVR) no. 28 10 63 51 (the "Company"), was held at c/o Mazanti-Andersen Advokatpartnerselskab, Amaliegade 10, DK-1256 Copenhagen K, Denmark. AGENDA AND RESOLUTIONS 1. Election of chairman of the meeting Attorney-at-law Lars Lüthjohan Jensen was elected as chairman of the meeting. 2. Proposal to authorize the Board of Dire...
Allarity Therapeutics Announces Extraordinary Exercise Period for Warr...
Allarity Therapeutics Announces Extraordinary Exercise Period for Warrants of Series ALLR TO 3 Set to August 30 – September 13, 2021 Press Release Hørsholm, Denmark (August 26, 2021) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announces that an accelerated extraordinary and final exercise period for warrants of the ALLR TO 3 series (the “TO 3 Warrants”), which were issued to subscribers of units in the Company's preferential rights issue in May-June 2021, starts on August 30 and runs until September 13. Each warrant entitles the holder to subscribe for one (1) newly is...
Allarity Therapeutics Files Form S-4 Registration Statement with U.S. ...
Allarity Therapeutics Files Form S-4 Registration Statement with U.S. Securities & Exchange Commission (SEC) for Listing on U.S. Nasdaq Company anticipates the first day of trading on U.S. Nasdaq will be during the fourth quarter, 2021A previously-announced U.S. $20 million investment by 3i Fund supports Company’s transition to the U.S. Nasdaq Press releaseHørsholm, Denmark (August 23, 2021) — Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced that its wholly-owned subsidiary, Allarity Therapeutics, Inc., a Delaware corporation, (hereinafter “Allarity US Inc.”). has ...
Allarity Therapeutics Publishes Interim Report for the Period January ...
Allarity Therapeutics Publishes Interim Report for the Period January – June 2021 Press ReleaseHørsholm, Denmark (August 23, 2021) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announces the publication of its Interim Report for the period January – June 2021. The report is available as an attached document and on the Company’s website. Steve Carchedi, CEO of Allarity Therapeutics, commented on the Company’s accomplishments during the period, stating , “In July, we successfully out-monetized our last remaining secondary pipeline program, irofulven. Shortly after our dives...
New Publication Date for Allarity Therapeutics’ Q2 2021 Interim Report
New Publication Date for Allarity Therapeutics’ Q2 2021 Interim Report Press ReleaseHørsholm, Denmark (August 19, 2021) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced a new publication date for the Company’s Q2 2021 Interim Report, which is now being made public on August 23, 2021 (previously: August 31, 2021). The reason for the change of publication date is to accelerate the Company’s preparations for the transformation and recapitalization as announced on May 21, 2021 as the Company advances towards migration to listing on the U.S. Nasdaq stock market (New Y...
Allarity Therapeutics Elaborates on the Contents of the Meeting Agenda...
Allarity Therapeutics Elaborates on the Contents of the Meeting Agenda for the Extraordinary General Meeting Announced on August 16, 2021 Press Release Hørsholm, Denmark (August 18, 2021) – Allarity Therapeutics A/S (“Allarity” or the “Company”) yesterday published a notice to convene an Extraordinary General Meeting on August 31, 2021. The Company hereby further elaborates on the information provided in the notice. Based on questions received from various shareholders with regard to the agenda item for the Extraordinary General Meeting to authorize the Board of Directors to purchase trea...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.